Celecoxib as Adjuvant Therapy to Chemotherapy in Patients With Metastatic Colorectal Cancer

Sherief Abd-Elsalam

Status and phase: Enrolling; Phase 4

Conditions: Colon Cancer Stage

Treatments: Drug: FOLFERI; Drug: Folferi and celecoxib

Study type: Interventional

Funder types: Other

Identifiers

NCT03645187

celecoxib

Details and patient eligibility

About

The study aimed at evaluation of anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer

Full description

The primary aim of the study is to evaluate the anticancer effect of celecoxib as adjuvant therapy to chemotherapy in patients with metastatic colorectal cancer

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• advanced colorectal cancer

Exclusion criteria

• cerebral metastases
• other malignancy
• H pylori infection
• thromboembolism

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

50 participants in 2 patient groups

FOLFERI

Active Comparator group

Description:

FOLFERI regien

Treatment:

Drug: FOLFERI

FOLFERI and celecoxib

Active Comparator group

Description:

FOLFERI and celecoxib

Treatment:

Drug: Folferi and celecoxib